HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Executive Decisions: Hardwick Heads US Apotex, Stada Adds To German Management, Lovett Leads Nutrition21 Marketing, More

Executive Summary

Hardwick heads Apotex in US; DSM expands cycling team support; Stada adds to Germany management; Lovett leads Nutrition21 marketing; Viatris appoints head of capital markets; and Redcon1 sponsors bodybuilder Greene, wrestler Omega.

You may also be interested in...



With ‘Significant Headroom For Growth,' Is Standalone Space Ahead For DSM Nutrition?

DSM says its nutrition segment, which includes human and animal nutrition and personal care, has a “unique business model combining 'global products' and 'local solutions'” and showed 6% organic sales growth for 2020 and 8% for Q4.

500 Days Later: Every Step Of Mylan And Upjohn’s Merger Into Viatris

Viatris, the combination of Mylan and Pfizer’s Upjohn unit, launched on 16 November. The culmination of almost 16 months of work, the transaction faced many hurdles, not least the devastating effects of the novel coronavirus pandemic. Generics Bulletin has collated every step of the deal in chronological order, spanning its 476-day history.

Viatris Plots ‘Significant’ Restructuring As Mylan-Upjohn Merger Completes

Nearly 16 months after it was first announced, the $12bn merger of Mylan and Pfizer’s Upjohn has completed, with the resulting company Viatris preparing to unveil restructuring plans by the end of 2020.

Related Companies

UsernamePublicRestriction

Register

RS150772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel